Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Opening Innovativeness: Moving Thoughts and Tasks - 2The top astronomical discoveries of 2025
- 3Surge of off‑lease electric vehicles expected to drive down used EV prices
- 4Former defense minister Gallant vacated home over security threat under Shin Bet direction
- 5UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- ‘Risk children’s lives for some extra manpower’: IRGC recruits 12 year olds to fill personnel gaps
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Seoul says sorry after unapproved drone flights into North Korea
- Are Saturn's rings made of a lost, shattered moon? New evidence arises for the case
- Overhaul Your Rest: Tips for a Serene Evening
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- Activist vessel collides with krill trawler in Antarctic confrontation
